Intensity Therapeutics Inc. (NASDAQ:INTS) Shares Shorted: Short Interest Up 129.4% in October

Intensity Therapeutics Inc. (NASDAQ:INTS) was the target of a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 87,767 shares, a growth of 129.4% from the September 30th total of 38,253 shares. Based on an average trading volume of 28,905 shares, the days-to-cover ratio is presently 3.0 days. Approximately 2.9% of the company’s shares are sold short.

Intensity Therapeutics Stock Performance

INTS stock traded up $0.06 during mid-day trading on Friday, reaching $3.40. 16,111 shares of the stock traded hands, compared to its average volume of 38,249. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 0.01. Intensity Therapeutics has a 52 week low of $3.00 and a 52 week high of $28.75. The business has a 50-day moving average of $3.80 and a two-hundred day moving average of $5.31. The firm has a market capitalization of $11.08 million, a PE ratio of -0.95 and a beta of 2.81.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.24). As a group, equities analysts predict that Intensity Therapeutics will post -2.64 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a research note on Monday, October 19th. Finally, HC Wainwright increased their target price on Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.00.

About Intensity Therapeutics

Intensity Therapeutics, Inc (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer.

The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent.